Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0924-8579(00)00245-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
From subsidies to stressors: Positively skewed ecological gradients alter biological responses to nutrients in streams.
Ecol Appl
January 2025
U.S. Geological Survey, Lower Mississippi-Gulf Water Science Center, Jackson, Mississippi, USA.
Subsidy-stress gradients offer a useful framework for understanding ecological responses to perturbation and may help inform ecological metrics in highly modified systems. Historic, region-wide shifts from bottomland hardwood forest to row crop agriculture can cause positively skewed impact gradients in alluvial plain ecoregions, resulting in tolerant organisms that typically exhibit a subsidy response (increased abundance in response to environmental stressors) shifting to a stress response (declining abundance at higher concentrations). As a result, observed biological tolerance in modified ecosystems may differ from less modified regions, creating significant challenges for detecting biological responses to restoration efforts.
View Article and Find Full Text PDFHighly Conductive, Ultratough, and Adhesive Eutectogels with Environmental Tolerance Enabled by Liquid Metal Composites.
Small
January 2025
School of Materials Science and Engineering, Suzhou University of Science and Technology, Suzhou, 215009, China.
Eutectogels are recently emerged as promising alternatives to hydrogels owing to their good environmental stability derived from deep eutectic solvents (DES). However, construction of competent eutectogels with both high conductivity and mechanical toughness is still difficult to achieve yet highly demanded. In this work, new LMNP-PEDOT-CMC-AA (LPCA) eutectogels are prepared using acrylic acid (AA) and carboxymethylcellulose sodium (CMC) as polymeric networks, liquid metal nanoparticle-poly(3,4-ethylenedioxythiophene) (LMNP-PEDOT) are added as multifunctional soft fillers.
View Article and Find Full Text PDFConstruing the resilience to osmotic stress using endophytic fungus in maize (Zea mays L.).
Plant Mol Biol
January 2025
Department of Plant Pathology, University of Agricultural Sciences, Gandhi Krishi Vignana Kendra (GKVK), Bengaluru, India.
In a wake of shifting climatic scenarios, plants are frequently forced to undergo a spectrum of abiotic and biotic stresses at various stages of growth, many of which have a detrimental effect on production and survival. Naturally, microbial consortia partner up to boost plant growth and constitute a diversified ecosystem against abiotic stresses. Despite this, little is known pertaining to the interplay between endophytic microbes which release phytohormones and stimulate plant development in stressed environments.
View Article and Find Full Text PDFA phase I study of MLN4924 and belinostat in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome.
Cancer Chemother Pharmacol
January 2025
Massey Comprehensive Cancer Center, Virginia Commonwealth University, Richmond, VA, USA.
Purpose: Relapsed and/or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome continue to have a poor prognosis with limited treatment options despite advancements in rational combination and targeted therapies. Belinostat (an HDAC inhibitor) and Pevonedistat (a NEDD8 inhibitor) have each been independently studied in hematologic malignancies and have tolerable safety profiles with limited single-agent activity. Preclinical studies in AML cell lines and primary AML cells show the combination to be highly synergistic, particularly in high-risk phenotypes such as p53 mutant and FLT-3-ITD positive cells.
View Article and Find Full Text PDFLerociclib plus fulvestrant in patients with HR+/HER2- locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy: LEONARDA-1 a phase III randomized trial.
Nat Commun
January 2025
Genor Biopharma Co., Ltd, Beijing, China.
Lerociclib (GB491), a highly selective oral CDK4/6 inhibitor, has displayed anti-tumor activity and differentiated safety and tolerability profile in previous ph1/2 clinical trials. The LEONARDA-1, a randomized, double-blind, phase III study, was conducted to evaluate the efficacy and safety of lerociclib in HR+/HER2- locally advanced or metastatic breast cancer patients, who had relapsed or progressed on prior endocrine therapy. A total of 275 patients were randomized at 1:1 ratio to receive lerociclib (137 patients, 150 mg twice daily) or placebo (138 patients) plus fulvestrant.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!